Case Information:

- **303** Patients diagnosed with LTBI
- **23** Cases per 100,000 people
- **53%** Decrease in cases since 2017

Demographics:
- 53% of patients were male
- 36 years old on average
- 5% Asian
- 69% Black
- 19% White
- 2% Pacific Islander
- 1% Hispanic
- 4% Unknown or Other Race

Geography:
- Patients were born in 39 different countries

Clinical Characteristics:
- 71% of patients (215) were treated with Rifampin
- 5% were a contact to a case of Active TB
- 11% lived in a congregate setting
- 16 patients were immunocompromised
- 4 patient reported substance abuse

Country of Birth:

<table>
<thead>
<tr>
<th>Country of Birth</th>
<th># Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRC</td>
<td>77</td>
</tr>
<tr>
<td>Angola</td>
<td>62</td>
</tr>
<tr>
<td>USA</td>
<td>55</td>
</tr>
<tr>
<td>Rwanda</td>
<td>22</td>
</tr>
</tbody>
</table>

Prevention:
- Test high-risk individuals and treat LTBI
- LTBI causes no symptoms and is not infectious; treating LTBI greatly reduces the risk of developing active TB disease.

For more information visit:
- [www.maine.gov/idepi](http://www.maine.gov/idepi)
- [www.cdc.gov/TB](http://www.cdc.gov/TB)

LTBI is not reportable in Maine; case data is estimated from patients are referred to the TB Control program for diagnostic and medication cost assistance.